Literature DB >> 20505746

Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma.

Tomomitsu Miyagaki1, Makoto Sugaya, Hideki Fujita, Hanako Ohmatsu, Takashi Kakinuma, Takafumi Kadono, Kunihiko Tamaki, Shinichi Sato.   

Abstract

CC chemokine receptor 3 (CCR3), the sole receptor for eotaxins, is expressed on eosinophils and T helper type 2 (Th2) cells. In Hodgkin's disease, eotaxin-1 secreted by fibroblasts collects Th2 cells and eosinophils within the tissue. Similarly, many Th2 cells infiltrate the lesional skin of cutaneous T-cell lymphoma (CTCL). In this study, we investigated the role of eotaxins in the development of the Th2 environment of CTCL. We revealed that fibroblasts from lesional skin of CTCL expressed higher amounts of eotaxin-3 messenger RNA (mRNA) compared with those from normal skin. Lesional skin of CTCL at advanced stages contained significantly higher levels of eotaxin-3 and CCR3 mRNA, compared with early stages of CTCL. IL-4 mRNA was expressed in some cases at advanced stages. Immunohistochemistry revealed that keratinocytes, endothelial cells, and dermal fibroblasts in lesional skin of CTCL showed a stronger expression of eotaxin-3 than did normal skin. CCR3(+) lymphocytes and IL-4 expression were observed in some cases of advanced CTCL. Furthermore, both serum eotaxin-3 and eotaxin-1 levels of CTCL patients at advanced stages were significantly higher than those of healthy individuals. The concentrations of these chemokines correlated with serum soluble IL-2 receptor levels. These results suggest that interaction of eotaxins and CCR3 regulates the Th2-dominant tumor environment, which is closely related to the development of CTCL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505746     DOI: 10.1038/jid.2010.128

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  26 in total

1.  Leukocyte cathepsin C deficiency attenuates atherosclerotic lesion progression by selective tuning of innate and adaptive immune responses.

Authors:  Veronica Herías; Erik A L Biessen; Cora Beckers; Dianne Delsing; Mengyang Liao; Mat J Daemen; Christine C T N Pham; Sylvia Heeneman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-13       Impact factor: 8.311

2.  Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma.

Authors:  Thorbjørn Krejsgaard; Ivan V Litvinov; Yang Wang; Lixin Xia; Andreas Willerslev-Olsen; Sergei B Koralov; Katharina L Kopp; Charlotte M Bonefeld; Mariusz A Wasik; Carsten Geisler; Anders Woetmann; Youwen Zhou; Denis Sasseville; Niels Odum
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

3.  Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma.

Authors:  Filiberto Cedeno-Laurent; Rei Watanabe; Jessica E Teague; Thomas S Kupper; Rachael A Clark; Charles J Dimitroff
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

4.  Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial.

Authors:  Pablo Vieyra-Garcia; Regina Fink-Puches; Stefanie Porkert; Roland Lang; Sophie Pöchlauer; Gudrun Ratzinger; Adrian Tanew; Sylvia Selhofer; Sator Paul-Gunther; Angelika Hofer; Alexandra Gruber-Wackernagel; Franz Legat; Vijaykumar Patra; Franz Quehenberger; Lorenzo Cerroni; Rachael Clark; Peter Wolf
Journal:  JAMA Dermatol       Date:  2019-05-01       Impact factor: 10.282

5.  Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma.

Authors:  Larisa J Geskin; Oleg E Akilov; Yan Lin; Anna E Lokshin
Journal:  Exp Dermatol       Date:  2014-07-16       Impact factor: 3.960

Review 6.  Novel Immunotherapies for T Cell Lymphoma and Leukemia.

Authors:  Paola Ghione; Alison J Moskowitz; Nadia E K De Paola; Steven M Horwitz; Marco Ruella
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

7.  Up-regulation of the chemokine CCL18 by macrophages is a potential immunomodulatory pathway in cutaneous T-cell lymphoma.

Authors:  Claudia Günther; Nick Zimmermann; Nicole Berndt; Marianne Grosser; Annette Stein; Andre Koch; Michael Meurer
Journal:  Am J Pathol       Date:  2011-07-08       Impact factor: 4.307

8.  Chemokine Receptor CCR3 Expression in Malignant Cutaneous Tumors.

Authors:  Yoon-Jin Lee; Dae-Hyun Kim; Sang-Han Lee; Hae-Seon Nam; Mi Ryung Roh; Moon-Kyun Cho
Journal:  Ann Dermatol       Date:  2010-11-05       Impact factor: 1.444

9.  Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.

Authors:  Anita Kumar; Santosha Vardhana; Alison J Moskowitz; Pierluigi Porcu; Ahmet Dogan; Jason A Dubovsky; Matthew J Matasar; Zhigang Zhang; Anas Younes; Steven M Horwitz
Journal:  Blood Adv       Date:  2018-04-24

10.  The role of IL-32 in cutaneous T-cell lymphoma.

Authors:  Hiraku Suga; Makoto Sugaya; Tomomitsu Miyagaki; Makiko Kawaguchi; Hideki Fujita; Yoshihide Asano; Yayoi Tada; Takafumi Kadono; Shinichi Sato
Journal:  J Invest Dermatol       Date:  2013-11-13       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.